Falls in men on androgen deprivation therapy for prostate cancer

Journal of Geriatric Oncology

Volumn 1, Issue 1, 2010, Pages 32-39

  Hussain, Shabbir ^a   Breunis, Henriette ^a   Timilshina, Narhari ^a   Alibhai, Shabbir M H ^a,b,c,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d TORONTO REHABILITATION INSTITUTE   (Canada)

Author keywords

Aged; Androgen deprivation; Falls; Men; Prostate cancer

Indexed keywords

AGED; ANDROGEN DEPRIVATION THERAPY; ARTHRITIS; ARTICLE; CONTROLLED STUDY; EMPLOYMENT STATUS; FALL RISK ASSESSMENT; FALLING; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; PHYSICAL PERFORMANCE; PREDICTION; PROSPECTIVE STUDY; PROSTATE CANCER;

EID: 77953738852     PISSN: 18794068     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgo.2010.03.004     Document Type: Article

References (42)

1. Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A., et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005, 97(19):1407-1427.
2. Potosky A.L., Reeve B.B., Clegg L.X., Hoffman R.M., Stephenson R.A., Albertsen P.C., et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst Monogr 2002, 94(6):430-437.
3. Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360(9327):103-106.
4. Ryan C.J., Small E.J. High risk biochemical relapse and the timing of androgen deprivation therapy. J Urol 2006, 176(6 Pt 2):S61-S65.
5. Loblaw D.A., Virgo K.S., Nam R., Somerfield M.R., Ben-Josef E., Mendelson D.S., et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007, 25(12):1596-1605.
6. Sharifi N., Gulley J.L., Dahut W.L. Androgen deprivation therapy for prostate cancer. Jama 2005, 294(2):238-244.
7. Alibhai S.M., Gogov S., Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 2006, 60(3):201-215.
8. Soyupek F., Soyupek S., Perk H., Ozorak A. Androgen deprivation therapy for prostate cancer: effects on hand function. Urol Oncol Semin Orig Investig 2008, 26(2):141-146.
9. Bylow K., Dale W., Mustian K., Stadler W.M., Rodin M., Hall W., et al. Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology 2008, 72(2):422-427.
10. The prevention of falls in later life A report of the Kellogg International Work Group on the Prevention of Falls by the Elderly. Dan Med Bull 1987, 34(Suppl 4):1-24.
11. Fuller G.F. Falls in the elderly. Am Fam Physician 2000, 61(7):2159-2168. 2173-4.
12. Tinetti M.E., Williams C.S. Falls, injuries due to falls, and the risk of admission to a nursing home. N Engl J Med 1997, 337(18):1279-1284.
13. Sattin R.W. Falls among older persons: a public health perspective. Annu Rev Public Health 1992, 13:489-508.
14. Ensrud K.E., Ewing S.K., Cawthon P.M., Fink H.A., Taylor B.C., Cauley J.A., et al. A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men. J Am Geriatr Soc 2009, 57(3):492-498.
15. Alibhai S.M., Duong-Hua M., Sutradhar R., Fleshner N.E., Warde P., Cheung A.M., et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009, 27(21):3452-3458.
16. Binkley N. A perspective on male osteoporosis. Best Pract Res Clin Rheumatol 2009, 23(6):755-768.
17. Solway S., Brooks D., Lacasse Y., Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 2001, 119(1):256-270.
18. Rantanen T., Volpato S., Ferrucci L., Heikkinen E., Fried L.P., Guralnik J.M. Handgrip strength and cause-specific and total mortality in older disabled women: exploring the mechanism. J Am Geriatr Soc 2003, 51(5):636-641.
19. Curb J.D., Ceria-Ulep C.D., Rodriguez B.L., Grove J., Guralnik J., Willcox B.J., et al. Performance-based measures of physical function for high-function populations. J Am Geriatr Soc 2006, 54(5):737-742.
20. Mathiowetz V., Kashman N., Volland G., Weber K., Dowe M., Rogers S. Grip and pinch strength: normative data for adults. Arch Phys Med Rehabil 1985, 66(2):69-74.
21. Guralnik J.M., Ferrucci L., Simonsick E.M., Salive M.E., Wallace R.B. Lower-extremity function in persons over the age of 70years as a predictor of subsequent disability. N Engl J Med 1995, 332(9):556-561.
22. Mathias S., Nayak U.S., Isaacs B. Balance in elderly patients: the "get-up and go" test. Arch Phys Med Rehabil 1986, 67(6):387-389.
23. Podsiadlo D., Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991, 39(2):142-148.
24. Mahoney F.I., Barthel D.W. Functional evaluation: the Barthel Index. Md State Med J 1965, 14:61-65.
25. Lawton M.P., Brody E.M. Assessment of older people: self-maintaining and instrument activities of daily living. Gerontologist 1969, 9:179-186.
26. Peduzzi P., Concato J., Kempter E., Holford T.R., Feinstein A.R. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996, 49:1373-1379.
27. Harrell F.E. Multivariable modeling strategies. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis 2001, 53-86. Springer-Verlag, New York. F.E. Harrell (Ed.).
28. Breunis H., Timilshina N., Tomlinson G., Naglie G., Tannock I., Fleshner N., et al. Declines in physical function from androgen deprivation therapy (ADT) in men with nonmetastatic prostate cancer. J Clin Oncol 2009, 27(Suppl. 15S):489s.
29. Basaria S., Lieb J., Tang A.M., DeWeese T., Carducci M., Eisenberger M., et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxford) 2002, 56(6):779-786.
30. Greenspan S.L., Coates P., Sereika S.M., Nelson J.B., Trump D.L., Resnick N.M. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005, 90(12):6410-6417.
31. Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352(2):154-164.
32. Bylow K., Mohile S.G., Stadler W.M., Dale W. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer? A conceptual review. Cancer 2007, 110(12):2604-2613.
33. Isbarn H., Boccon-Gibod L., Carroll P.R., Montorsi F., Schulman C., Smith M.R., et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009, 55(1):62-75.
34. Guideline for the prevention of falls in older persons American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on falls prevention. J Am Geriatr Soc 2001, 49(5):664-672.
35. Gates S., Fisher J.D., Cooke M.W., Carter Y.H., Lamb S.E. Multifactorial assessment and targeted intervention for preventing falls and injuries among older people in community and emergency care settings: systematic review and meta-analysis. Bmj 2008, 336(7636):130-133.
36. Sbarra D.A. Marriage protects men from clinically meaningful elevations in C-reactive protein: results from the National Social Life, Health, and Aging Project (NSHAP). Psychosom Med 2009, 71:828-835.
37. Segal R.J., Reid R.D., Courneya K.S., Malone S.C., Parliament M.B., Scott C.G., et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003, 21(9):1653-1659.
38. Galvao D.A., Nosaka K., Taaffe D.R., Spry N., Kristjanson L.J., McGuigan M.R., et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 2006, 38(12):2045-2052.
39. Banez C., Tully S., Amaral L., Kwan D., Kung A., Mak K., et al. Development, implementation, and evaluation of an interprofessional falls prevention program for older adults. J Am Geriatr Soc 2008, 56(8):1549-1555.
40. Taylor L.G., Canfield S.E., Du X.L. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009, 115(11):2388-2399.
41. Panju A.H., Breunis H., Cheung A.M., Leach M., Fleshner N., Warde P., et al. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int 2009, 103(6):753-757.
42. Huggins C., Hodges C.V. The effect of castration and estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293-299.